Parkville Precinct

Australia's leading health, biomedical and research hub.

The Parkville Precinct,  previously known as the Melbourne Biomedical Precinct – gives investors direct access to Australia’s strongest concentration of research excellence, industry partners and talent.

As Australia’s premier biomedical hub and one of the most respected globally, it drives innovation through groundbreaking research, advanced clinical care and training for the nation’s top clinical and scientific talent.

With Parkville Station opening in 2025 as part of the Metro Tunnel, it will be even more tightly connected to Melbourne’s innovation spine, enhancing access for industry, talent and global partners.

We can help you find the right location or partnership.

At a glance

• Just 2km from Melbourne’s CBD
• 73,000 people employed across biomedical research, clinical innovation and education
• $3.6 billion annual economic contribution
• $1b+ in competitive biomedical research funding secured each year
• Over 40 globally recognised biomedical organisations co-located within one high-performing precinct
• 20% of Australia’s health-related patents originate from Parkville institutions

Why Parkville?

World-class biomedical ecosystem

• Parkville offers globally unique concentration of research institutes, universities, companies and collaborative infrastructure.
• A proven track record of innovation, with global companies choosing Parkville to develop and scale biomedical solutions.
• Dense cluster accelerates partnerships, knowledge sharing, and access to advanced facilities.

Major companies

• CSL Limited
• BioGrid Australia
• Melbourne Bioinformatics
• Melbourne Brain Centre
• Australian Genome Research Facility
• Bio21 Molecular Science and Biotechnology Institute
• National Ageing Research Institute

Major hospitals

• The Royal Melbourne Hospital
• The Royal Children’s Hospital
• The Royal Women’s Hospital
• Frances Perry House

Major medical research institutes

• Walter and Eliza Hall Institute of Medical Research (WEHI)
• Victorian Comprehensive Cancer Centre (VCCC)
• The Florey Institute of Neuroscience and Mental health
• Murdoch Children’s Research Institute
• Peter Doherty Institute for Infection and Immunity
• Peter MacCallum Cancer Centre
• CSIRO

Universities

• University of Melbourne
• Monash University, including Monash Institute of Pharmaceutical Science
• RMIT University

End-to-end biomedical innovation

• Complete pipeline for biomedical investment – discovery research, clinical trials, product development, biomanufacturing and commercialisation.
• Leading-edge focus areas include genomics, immunology, cancer, neuroscience, paediatric medicine, infectious diseases and digital health innovation.
• Central to Australia’s vaccine development and pandemic response.

Access top talent and global networks

• Home to Australia’s top clinical, scientific and technical professionals.
• Close links to global research and industry partners, facilitation collaboration and market expansion.
• Enhanced connectivity with new Parkville Station opened 2025 that links the precinct to Melbourne’s innovation spine, supply chains and customers.

Supportive government policy for Parkville and lifesciences

• Parkville Precinct Opportunity Statement -  sets a vision for global leadership in biomedical innovation.
• Victorian Government’s Health and Medical Research Strategy: 2022-2032 - identifies the precinct as a flagship site for advanced biomedical research, sovereign capability and global partnerships.

Recent major investments

• Metro Tunnel – new Parkville Station
• CSL global headquarters
• Jumar Bioincubator ($95 million) - a joint initiative between CSL, the University of Melbourne, Walter and Eliza Hall Institute (WEHI) and Breakthrough Victoria
• Australian Institute for Infectious Disease ($650 million)
• Cumming Global Centre for Pandemic Therapeutics ($325+ million)

Need assistance? We are here to help

We can help you better understand how Parkville Precinct may benefit your business.